TY - JOUR T1 - Antibodies against type-I Interferon: detection and association with severe clinical outcome in COVID-19 patients JF - medRxiv DO - 10.1101/2021.04.02.21253262 SP - 2021.04.02.21253262 AU - Goncalves David AU - Mezidi Mehdi AU - Bastard Paul AU - Perret Magali AU - Saker Kahina AU - Fabien Nicole AU - Pescarmona Rémi AU - Lombard Christine AU - Walzer Thierry AU - Casanova Jean-Laurent AU - Belot Alexandre AU - Richard Jean-Christophe AU - Trouillet-Assant Sophie Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/04/2021.04.02.21253262.abstract N2 - Objectives Impairment of type I interferon (IFN-I) immunity has been reported in critically-ill COVID-19 patients. This defect can be explained in a subset of patients by the presence of circulating autoantibodies (auto-Abs) against IFN-I. We set out to improve the detection and the quantification of IFN-I auto-Abs in a cohort of critically-ill COVID-19 patients, in order to better evaluate the prevalence of these Abs as the pandemic progresses, and how they correlate with the clinical course of the disease.Methods The concentration of anti-IFN-α2 Abs was determined in the serum of 84 critically-ill COVID-19 patients who were admitted to ICU in Hospices Civils de Lyon, France using a commercially available kit (Thermo-Fisher, Catalog #BMS217).Results A total of 21/84 (25%) critically-ill COVID-19 patients had circulating anti-IFN-α2 Abs above cut-off (>34 ng.mL-1). Among them, 15/21 had Abs with neutralizing activity against IFN-α, i.e. 15/84 (18%) of critically-ill patients. In addition, we noticed an impairment of the IFN-I response in the majority of patients with neutralizing anti-IFN-α2 Abs. There was no significant difference in the clinical characteristics or outcome of with or without neutralizing anti-IFN-α2 auto-Abs. We detected anti-IFN-α2 auto-Abs in COVID-19 patients’ sera throughout their ICU stay. Finally, we also found auto-Abs against multiple subtypes of IFN-I including IFN-ω.Conclusions We reported that 18% of critically-ill COVID-19 patients were positive for IFN-I auto-Abs, confirming the detrimental role of these Abs in the antiviral response.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04341142Clinical Protocols https://pubmed.ncbi.nlm.nih.gov/33234651/ Funding StatementThis research is being supported by Hospices Civils de Lyon and by Fondation des Hospices Civils de Lyon.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Concerning severe COVID-19 patients, this study was registered to the French National Data Protection Agency under the number 20-097 and was approved by an ethical committee for biomedical research (Comite de Protection des Personnes HCL) under the number 20-41. In agreement with the General Data Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the French data protection law (Law number 78-17 on 06/01/1978 and Decret number 2019-536 on 29/05/2019), we obtained consent from each patient or his next of kin. Concerning mild COVID-19 patients, written informed consent was obtained from all participants; ethics approval was obtained from the national review board for biomedical research in April 2020 (Comite de Protection des Personnes Sud Mediterranee I, Marseille, France; ID RCB 2020-A00932-37), and the study was registered on ClinicalTrials.gov (NCT04341142).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, STA, upon reasonable request. ER -